Description,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM
CWNVEQARF,Positive-High,,1925.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3010317727472659
RVAVILNEF,Positive-High,,2530.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2757730911166582
KYISTSLPV,Positive-High,,7135.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1799492284703009
IWEQLASRF,Positive-High,,6405.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1899247855235927
FFNKGGSVF,Positive-Intermediate,,13260.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.1226708150372021
LMKGGANLF,Positive-Intermediate,,26720.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0579134470493315
LFTKLHPAF,Positive-Intermediate,,19600.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0865538474610913
SYYMPQLFW,Positive-Intermediate,,27770.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.0543510863763961
EMQSLHFAF,Positive-High,,4845.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.2157230673985694
KYSDVIKVL,Positive-High,,1376.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3320624666675245
DYPGQGFSF,Positive-High,,5841.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.198444083966458
RFTLSVPGF,Positive-High,,1597.0,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.3182963685270169
VYSFLCKTI,Positive-High,,606.9,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.4077176200481553
QYDPVAALF,Positive-High,,707.4,nM,HLA-A*24:02,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/competitive/fluorescence,half maximal inhibitory concentration (IC50),Homo sapiens (human),9,0.393555384935597
HYSPLILAL,Positive,,64.0,nM,HLA-A*24:02,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.6156221528723917
